PubRank

R W Coombs

Author PubWeight™ 124.71‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010 12.08
2 Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998 5.45
3 Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991 5.42
4 Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS 2001 4.76
5 Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996 4.44
6 Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996 4.43
7 Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med 1987 3.42
8 A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med 1990 2.48
9 Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med 1995 2.26
10 Rapid and sensitive viral culture method for human immunodeficiency virus type 1. J Clin Microbiol 1988 2.22
11 Viricidal effect of Lactobacillus acidophilus on human immunodeficiency virus type 1: possible role in heterosexual transmission. J Exp Med 1991 2.04
12 Infection of Macaca nemestrina by human immunodeficiency virus type-1. Science 1992 2.01
13 Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology 2003 1.83
14 The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements. The Women Infant Transmission Study Clinics. Virology Quality Assurance Program. AIDS 1999 1.70
15 Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons. J Clin Microbiol 1998 1.60
16 Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci U S A 1993 1.58
17 Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. J Infect Dis 1995 1.57
18 Recovery of human immunodeficiency virus type 1 from semen: minimal impact of stage of infection and current antiviral chemotherapy. J Infect Dis 1991 1.57
19 Effect of menstrual cycle on HIV-1 levels in the peripheral blood and genital tract. WHS 001 Study Team. AIDS 2000 1.54
20 A menstrual cycle pattern for cytokine levels exists in HIV-positive women: implication for HIV vaginal and plasma shedding. AIDS 2001 1.45
21 Transmission of genital herpes in couples with one symptomatic and one asymptomatic partner: a prospective study. J Infect Dis 1988 1.44
22 Genetic evaluation of suspected cases of transient HIV-1 infection of infants. Science 1998 1.43
23 Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993 1.42
24 Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS 1998 1.40
25 The effect of light on the antibacterial activity of beta-thujaplicin. Can J Microbiol 1973 1.32
26 Intermittent shedding of human immunodeficiency virus in semen: implications for sexual transmission. J Urol 1995 1.27
27 Association of antiretroviral therapy with detection of HIV-1 RNA and DNA in the anorectal mucosa of homosexual men. AIDS 2000 1.27
28 Indeterminate human immunodeficiency virus type 1 western blots: seroconversion risk, specificity of supplemental tests, and an algorithm for evaluation. J Infect Dis 1991 1.24
29 Markers of HIV infection prior to IgG antibody seropositivity. JAMA 1989 1.24
30 Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998 1.23
31 Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with > or = 400 CD4 lymphocytes: implications for applying measurements to individual patients. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1997 1.22
32 Risk factors for repeatedly reactive HIV-1 EIA and indeterminate western blots. A population-based case-control study. Arch Intern Med 1994 1.22
33 Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998 1.20
34 Viricidal effect of polymorphonuclear leukocytes on human immunodeficiency virus-1. Role of the myeloperoxidase system. J Clin Invest 1992 1.20
35 Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. Ann Intern Med 2001 1.18
36 Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin Infect Dis 1995 1.16
37 Vasectomy and human immunodeficiency virus type 1 in semen. J Urol 1998 1.13
38 Risk factors for HIV-1 shedding in semen. Am J Epidemiol 1999 1.12
39 The effects of high-dose recombinant soluble CD4 on human immunodeficiency virus type 1 viremia. J Infect Dis 1994 1.10
40 Phase I study of cellular adoptive immunotherapy using genetically modified CD8+ HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Department of Medicine, Division of Oncology. Hum Gene Ther 1992 1.09
41 Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. J Infect Dis 1996 1.07
42 Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology 2011 1.07
43 Performance characteristics of the QUANTIPLEX HIV-1 RNA 3.0 assay for detection and quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2000 1.05
44 Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial. J Infect Dis 1995 1.04
45 The HIV type 1 protease inhibitor saquinavir can select for multiple mutations that confer increasing resistance. AIDS Res Hum Retroviruses 1999 1.04
46 Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333. J Infect Dis 2000 1.04
47 Antibacterial activity of beta-thujaplicin. Can J Microbiol 1973 1.04
48 Unintegrated circular HIV-1 DNA in the peripheral mononuclear cells of HIV-1-infected subjects: association with high levels of plasma HIV-1 RNA, rapid decline in CD4 count, and clinical progression to AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998 1.02
49 Arrangement of morphological subunits in bacterial spinae. Can J Microbiol 1976 1.02
50 Transmission of genital herpes by donor insemination. JAMA 1989 1.01
51 HIV-1 dynamics in children. J Acquir Immune Defic Syndr Hum Retrovirol 1999 0.99
52 Multicenter evaluation of methods to quantitate human immunodeficiency virus type 1 RNA in seminal plasma. J Clin Microbiol 2000 0.98
53 Absence of detectable human herpesvirus 8 in the semen of human immunodeficiency virus-infected men without Kaposi's sarcoma. J Infect Dis 1997 0.97
54 Cytokine activation of human macrophages infected with HIV-1 to inhibit intracellular protozoa. J Acquir Immune Defic Syndr 1992 0.96
55 Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro. J Med Virol 1999 0.96
56 Acute infection of Macaca nemestrina by human immunodeficiency virus type 1. Virology 1993 0.96
57 The effects of zidovudine in the subset of infants infected with human immunodeficiency virus type-1 (Pediatric AIDS Clinical Trials Group Protocol 076). J Pediatr 1999 0.94
58 Seminal shedding of human immunodeficiency virus type 1 and human cytomegalovirus: evidence for different immunologic controls. J Infect Dis 1995 0.92
59 Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women. J Acquir Immune Defic Syndr Hum Retrovirol 1997 0.90
60 Comparison of assays to detect cytomegalovirus shedding in the semen of HIV-infected men. J Virol Methods 2000 0.89
61 Effects of clinical stage and immunological status on semen analysis results in human immunodeficiency virus type 1-seropositive men. Andrologia 1998 0.88
62 Spinin: the subunit protein of bacterial spinae. Can J Microbiol 1976 0.86
63 Trichinosis with ventilatory failure and persistent myocarditis. Clin Infect Dis 1993 0.85
64 Combination therapy with zidovudine, didanosine and saquinavir. Antiviral Res 1996 0.85
65 Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories. J Infect Dis 1994 0.84
66 Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop. Stat Med 1998 0.83
67 A randomized, double-blind, phase I/II trial of tumor necrosis factor and interferon-gamma for treatment of AIDS-related complex (Protocol 025 from the AIDS Clinical Trials Group). AIDS Res Hum Retroviruses 1992 0.82
68 Progression of human immunodeficiency virus type-1 infection after allogeneic marrow transplantation. Am J Med 1990 0.81
69 Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229. J Infect Dis 1999 0.81
70 Fertility parameters in men infected with human immunodeficiency virus. J Infect Dis 1991 0.81
71 Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease. J Infect Dis 2000 0.80
72 Virologic parameters as surrogate markers for clinical outcome in HIV-1 disease: verification, variation, and validation. J Acquir Immune Defic Syndr Hum Retrovirol 1995 0.79
73 Acquired immunodeficiency syndrome. Cerebrospinal fluid findings in patients before and during long-term oral zidovudine therapy. Arch Neurol 1991 0.78
74 Cognitive risk factors and neuropsychological performance in HIV infection. Int J Neurosci 1993 0.78
75 The natural history of HIV infection: implications for the assessment of antiretroviral therapy. Clin Infect Dis 1993 0.78
76 Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials Group. J Clin Microbiol 1996 0.77
77 Virucidal effect of stimulated eosinophils on human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1996 0.77
78 The attachment of bacterial spinae. Can J Microbiol 1977 0.77
79 Determination of indinavir, a HIV-1 protease inhibitor, in human plasma using ion-pair reversed-phase high-performance liquid chromatography. Ther Drug Monit 1999 0.76
80 Effect of zidovudine on perinatal HIV-1 transmission and maternal viral load. Pediatric AIDS Clinical Trials Group 076 Study Group. Lancet 1999 0.75
81 Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex. J Acquir Immune Defic Syndr Hum Retrovirol 1995 0.75
82 Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team. Blood 2000 0.75
83 Neurologic Manifestations<br />of HIV Infection Without AIDS:Follow-UP of a Cohort<br />of Homosexual and Bisexual Men. J NeuroAIDS 1996 0.75
84 Comparative studies on the structures of the heat labile beta-N-acetylhexosaminidases from human plasma and placenta. Int J Biochem 1977 0.75
85 Indeterminate HIV-1 western blots: implications and considerations for widespread HIV testing. J Gen Intern Med 1993 0.75
86 Interference of recombinant soluble CD4 immunoglobulin G in flow cytometric measurement of CD4+ lymphocytes. Am J Clin Pathol 1992 0.75
87 Cartesian coordinate analysis of viral burden and CD4+ T-cell count in human immunodeficiency virus type-1 infection. Antiviral Res 1998 0.75
88 Cartesian coordinate analysis of viral burden and CD4+ cell count in HIV disease: implications for clinical trial design and analysis. Antiviral Res 1996 0.75
89 Prospective cerebral MR study of HIV seropositive and seronegative men: correlation of MR findings with neurologic, neuropsychologic, and cerebrospinal fluid analysis. AJNR Am J Neuroradiol 1992 0.75
90 Central nervous system manifestations in human immunodeficiency virus infection without AIDS. J Acquir Immune Defic Syndr 1992 0.75
91 Protein conformation in bacterial spinae. Biopolymers 1976 0.75
92 Physicochemical and immunological homogeneity of spinin, the subunit-protein of bacterial spinae. Biochim Biophys Acta 1978 0.75